More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.71B
EPS
-1.09
P/E ratio
--
Price to sales
24.53
Dividend yield
--
Beta
2.322051
Previous close
$15.98
Today's open
$15.93
Day's range
$15.86 - $16.11
52 week range
$4.96 - $18.89
show more
CEO
Christopher Hall
Employees
229
Headquarters
Fremont, CA
Exchange
NASDAQ Global Market
Shares outstanding
106799872
Issue type
Common Stock
Healthcare
Medical Diagnostics & Screening
PSNL Merger Notice: BFA Law Notifies Personalis Shareholders of the Ongoing Investigation into the $16.25 per Share Merger
BFA Law is investigating the announced $16.25 per share merger in which Tempus AI, Inc., a commercial associate of Personalis, is set to acquire all outstanding Personalis stock; current stockholders are notified to contact the firm. New York, New York--(Newsfile Corp. - October 29, 2026) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that it is investigating the going private merger whereby Personalis, Inc. (NASDAQ: PSNL) is being taken private by Tempus AI, Inc. Personalis is incorporated in Delaware.
Newsfile Corp • 14 hours ago

$PSNL Stock Market Alert: Personalis' $16.25 per Share Merger Is Under Investigation – Contact BFA Law if You Are a Shareholder
NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that it is investigating the going private merger whereby Personalis, Inc. (NASDAQ: PSNL) is being taken private by Tempus AI, Inc. Personalis is incorporated in Delaware. If you are a current stockholder of Personalis, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/personalis-merger-investigation.
GlobeNewsWire • Oct 28, 2026

PSNL Investor Investigation: Personalis Shareholders Are Alerted to the Pending Investigation into the $16.25 per Share Merger
BFA Law is investigating the announced $16.25 per share merger in which Tempus AI, Inc., a commercial associate of Personalis, is set to acquire all outstanding Personalis stock; current stockholders are notified to contact the firm. NEW YORK, Oct. 27, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that it is investigating the going private merger whereby Personalis, Inc. (NASDAQ: PSNL) is being taken private by Tempus AI, Inc. Personalis is incorporated in Delaware.
PRNewsWire • Oct 27, 2026

$PSNL Merger Investigation: BFA Law Reminds Personalis Shareholders of Its Ongoing Investigation into the $16.25 per Share Merger Deal
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that it is investigating the going private merger whereby Personalis, Inc. (NASDAQ: PSNL) is being taken private by Tempus AI, Inc. Personalis is incorporated in Delaware. If you are a current stockholder of Personalis, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/personalis-merger-investigation.
GlobeNewsWire • Oct 26, 2026

PERSONALIS, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Personalis, Inc.'s Directors and Officers for Breach of Fiduciary Duties – PSNL
Scott+Scott Attorneys at Law LLP is investigating whether the directors of Personalis, Inc. breached their fiduciary duties to Personalis's shareholders.
GlobeNewsWire • Oct 26, 2026

Investor Notification: Personalis, Inc. ($PSNL) Investors Are Reminded to Contact BFA Law About the Ongoing Investigation into $16.25 per Share Merger Deal
BFA Law is investigating the announced $16.25 per share merger in which Tempus AI, Inc., a commercial associate of Personalis, is set to acquire all outstanding Personalis stock; current stockholders are notified to contact the firm. New York, New York--(Newsfile Corp. - October 24, 2026) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that it is investigating the going private merger whereby Personalis, Inc. (NASDAQ: PSNL) is being taken private by Tempus AI, Inc. Personalis is incorporated in Delaware.
Newsfile Corp • Oct 24, 2026

PSNL Investigation News: Personalis, Inc. Investors are Notified of the Pending Investigation into Ongoing Merger – Contact BFA Law if You Hold Shares
NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that it is investigating the going private merger whereby Personalis, Inc. (NASDAQ: PSNL) is being taken private by Tempus AI, Inc. Personalis is incorporated in Delaware. If you are a current stockholder of Personalis, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/personalis-merger-investigation.
GlobeNewsWire • Oct 23, 2026

PSNL Securities Notice: Personalis, Inc. Shareholders Are Notified to Contact BFA Law About Its Pending Investigation into the $16.25 per Share Merger Deal
BFA Law is investigating the announced $16.25 per share merger in which Tempus AI, Inc., a commercial associate of Personalis, is set to acquire all outstanding Personalis stock; current stockholders are notified to contact the firm. New York, New York--(Newsfile Corp. - October 22, 2026) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that it is investigating the going private merger whereby Personalis, Inc. (NASDAQ: PSNL) is being taken private by Tempus AI, Inc. Personalis is incorporated in Delaware.
Newsfile Corp • Oct 22, 2026

PSNL Stock Notification: Personalis, Inc. is being Investigated after the $16.25 per share Merger Deal Announced – Investors are Alerted to Contact BFA Law
NEW YORK--(BUSINESS WIRE)---- $PSNL #Acquisition--Personalis, Inc. is being Investigated after the $16.25 per share Merger Deal Announced – Investors are Alerted to Contact BFA Law.
Business Wire • Oct 21, 2026

Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that two oral presentations and two poster presentations featuring its NeXT Personal ultrasensitive circulating tumor DNA (ctDNA) test will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain. Highlights include a late-breaking oral presentation of NeXT Personal data for the C-POST Phase 3.
Business Wire • Oct 21, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Personalis Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.